Share

Study QUINTILES- PT#:201038 – Post authorization safety (PAS) observational cohort study to quantify the incidence and comparative safety of selected cardiovascular and cerebrovascular events in copd patients using inhaled UMEC/VI combination or inhaled UMEC versus Tiotropium

Project objectives

Primary endpoint: evaluation of the cardiovascular and cerebrovascular safety profiles of inhaled therapies in combination or monotherapy in patients with COPD.

Start and end date

May 2017 - Completed in 2023

Project Manager

Simone Scarlata - Principal Investigator

Coordinating institution of the project

Campus Bio Medico Polyclinic Foundation

Other Institutions involved

  • Multicenter international study

Funding source(s).

• GlaxoSmithKline SpA Viale dell'Agricoltura, 7 37135 Verona
magnifiercrossmenuchevron-downchevron-leftchevron-right